Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golden Bifid for diarrhea-predominant irritable bowel syndrome (IBS-D)
ChiCTR2400088770Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing Golden Bifid with Placebo (2 arms). Primary endpoints: Effective rate of treatment for 4 weeks, Adverse event occurrence rate and 1 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
bifidobacterium triple viable
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR2400088770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088770.